论文部分内容阅读
目的:探讨BubR1基因在紫杉醇治疗肿瘤中的作用。方法:构建针对BUBR1基因的特异性短发夹RNA载体,导入人肝癌细胞株HepG-2,转染48 h后,运用实时荧光定量PCR、Western印迹法评价RNA干扰效果;BubR1表达下调的肝癌细胞及对照组细胞用不同浓度(1、3、10、30、100、300、1000和3000 nmol/L)的紫杉醇处理,MTT法检测细胞增殖情况。结果:shRNA-BubR1可有效抑制BubR1的mRNA、蛋白水平以及内源性表达。MTT结果显示,BubR1表达下调的细胞在不同浓度紫杉醇作用下的增殖抑制率与对照组相比明显增加(P<0.05),并呈现剂量依赖性。结论:下调BubR1的表达能增强肝癌细胞对紫杉醇的敏感性。
Objective: To investigate the role of BubR1 in paclitaxel-treated tumors. Methods: The specific short hairpin RNA (shRNA) vector targeting BUBR1 gene was constructed and transfected into human hepatocellular carcinoma cell line HepG-2. 48 h after transfection, RNA interference was evaluated by real-time fluorescence quantitative PCR and Western blotting. And control cells were treated with different concentrations of paclitaxel (1, 3, 10, 30, 100, 300, 1000 and 3000 nmol / L), MTT assay cell proliferation. RESULTS: shRNA-BubR1 effectively inhibited BubR1 mRNA and protein levels as well as endogenous expression. The results of MTT showed that the inhibition rate of BubR1-down-regulated cells in paclitaxel group was significantly increased compared with that in control group (P <0.05), and showed a dose-dependent manner. Conclusion: Down-regulation of BubR1 expression can enhance the sensitivity of hepatoma cells to paclitaxel.